Shares of Tesaro Inc. (NASDAQ:TSRO) reached a new 52-week high on Monday . The company traded as high as $99.28 and last traded at $98.64, with a volume of 1,074,303 shares trading hands. The stock had previously closed at $95.03.

TSRO has been the subject of a number of analyst reports. FBR & Co increased their price objective on Tesaro from $65.00 to $93.00 and gave the company an “outperform” rating in a research note on Wednesday, June 29th. Mizuho increased their price objective on Tesaro from $67.00 to $94.00 and gave the company a “buy” rating in a research note on Tuesday, July 5th. Robert W. Baird initiated coverage on Tesaro in a research note on Monday, July 18th. They set an “outperform” rating and a $105.00 price objective for the company. Jefferies Group lowered Tesaro from a “buy” rating to a “hold” rating and increased their price objective for the company from $53.00 to $75.00 in a research note on Thursday, June 30th. They noted that the move was a valuation call. Finally, Leerink Swann increased their price objective on Tesaro from $65.00 to $95.00 and gave the company an “outperform” rating in a research note on Thursday, June 30th. Two research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $85.50.

The stock’s market capitalization is $5.04 billion. The stock has a 50-day moving average price of $91.42 and a 200-day moving average price of $55.21.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($1.71) by $0.43. During the same period in the previous year, the firm earned ($1.51) EPS. The firm earned $36.60 million during the quarter, compared to the consensus estimate of $4.98 million. Analysts forecast that Tesaro Inc. will post ($7.31) EPS for the current year.

In other Tesaro news, VP Jeffrey H. Hanke sold 12,500 shares of Tesaro stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total value of $929,375.00. Following the sale, the vice president now owns 12,500 shares of the company’s stock, valued at approximately $929,375. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction that occurred on Friday, June 10th. The stock was sold at an average price of $40.75, for a total value of $285,250.00. Following the completion of the sale, the vice president now directly owns 3,500 shares in the company, valued at approximately $142,625. The disclosure for this sale can be found here.

Other institutional investors recently added to or reduced their stakes in the company. Jennison Associates LLC increased its position in Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock valued at $49,100,000 after buying an additional 574,041 shares in the last quarter. Bank of Montreal Can increased its position in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock valued at $1,275,000 after buying an additional 24,119 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares in the last quarter.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.